PATENT Docket No. 249.0007 0101

	IN THE UNITED STATES	PATEN	T AND TRADEMARK OFFICE	DEACH			
	Dominic COSGROVE)	Group Art Unit: 1644	RECEIVED CENTRAL FAX CENTER			
Serial No.: Confirmation	10/698,121 No.: 8958)))	Examiner: Maher M. Haddad	JAN 1 0 2006			
Filed:	31 October 2003)					
For:	INDUCIBLE LIGAND FO	OR α1β1	INTEGRIN AND USES				
	FACSIMILE TR	RANSMI	SSION TO THE PTO				
Mail Stop Am	endment						
Commissioner	r for Patents		FAX NUMBER: _(571) 273-83	300			
Attn: Examine	er <u>H</u> addad		Total Pages (including cover page	18). H			
P.O. Box 1450			Time: 1:45 pm (Central 7	Cime)			
Alexandria, VA 22313-1450			(Transmission must be complete by midnight eastern time.)				
The following transmission:			Patent and Trademark Office by fac	esimile			
$\frac{X}{X}$	Response to Restriction I Small Entity Status is entapplication.	Requiren titled to l	nent (3 pgs) oe asserted in the above-identifie	d			
Please consider these papers and	this a PETITION FOR EXTEN I please charge any additional f	SION OF	TIME for a sufficient number of mont lit overpayment to Deposit Account No	hs to enter . 13-4895.			
			ing, Raasch & Gebhardt, P.A. mer Number: 26813				
Date	10,2006	By:	Maryd. Johnson				
	J	•	No. 47,266				
			t Dial (612)305-4723				
<u>CERTIFICATE</u>	UNDER 37 C.F.R. §1.8: The u	ndersigned	hereby certifies that this Facsimile Cove	r Sheet and the			
paper(s), as descri and Trademark Or	ibed hereinabove, are being transi ffice addressed to the Mail Stop A	mitted by fa mendment.	acsimile in accordance with 37 CFR §1.6(Commissioner for Patents, Attn: Examine of <u>January</u> , 2006, at <u>1:45pm</u>	d) to the Patent			
LO JANUARY Date	2006	Signat	ure: togymany				
		Printed	1 Name: Keily J. McNuty				

RECEIVED
CENTRAL FAX CENTER

JAN 1 0 2003

PATENT Docket No. 249,0007 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Dominic COSGROVE)	Group Art Unit: 1644			
Serial No.: Confirmation)	Examiner:	Maher M. Haddad		
Filed:	31 October 2003)				
For:	INDUCIBLE LIGAND FOR albi INTEGRIN AND USES					

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed 16 December 2005, Applicant elects, with traverse, Group II (claims 3, 5, 10-11, 15, 21, and 25), drawn to a method of treating a patient having a chronic inflammatory disease with a blocking agent wherein the blocking agent is an antibody. In consideration that Group II is elected (with traverse), Applicant further elects the species of renal fibrosis. Applicant reserves the right to pursue examination of the non-elected claims in continuation or divisional applications.

Applicant acknowledges the Examiner's identification of claims 1, 2, 6-8, 12, 13, 17-19, 22, and 23 as linking claims, linking the inventions of Groups I and II (page 2, Restriction Requirement mailed December 16, 2005). However, Applicant respectfully submits that claims 3 and 11 are to be included in this listing of linking claims, as both are drawn to a method comprising administering an agent. Further, Applicant respectfully submits that linking claims 1-3, 6-8, 11-13, 17-19, 22, and 23 link the inventions of not only Groups I (wherein the agent is a peptide) and Group II (wherein the agent is an antibody), but also link the invention of Group III (wherein the agent is a small inhibitory RNA).

Page 2 of 3

Response to Restriction Requirement

Applicant(s): Serial No.: Dominic COSGROVE 10/698,121

Filed:

31 October 2003

For:

INDUCIBLE LIGAND FOR a1B1 INTEGRIN AND USES

According to MPEP § 809, "linking claims must be examined with, and thus are considered part of, the invention elected. When all claims directed to the elected invention are allowable, should any linking claim be allowable, the restriction requirement between the linked inventions must be withdrawn. Any claim(s) directed to the nonelected invention(s), previously withdrawn from consideration, which depends from or requires all the limitations of the allowable linking claim must be rejoined and will be fully examined for patentability." Thus, Applicant submits that linking claims 1-3, 6-8, 11-13, 17-19, 22, and 23 (drawn a method comprising the administration of an agent) are to be fully examined, in their entirety, in the next Office Action. Applicant respectfully submits that the examination of linking claims 1-3, 6-8, 11-13, 17-19, 22, and 23 is not to be limited in scope to the elected invention of Group II, wherein the agent is an antibody.

Applicant respectfully requests reconsideration and withdrawal or modification of the restriction requirement. It is respectfully submitted that the inventions as claimed can be readily evaluated in one search without placing undue burden on the Examiner. That is, all the claims are so interrelated that a search of one group of claims will reveal art to the others. In particular, it is requested that Group I be rejoined with Group II.

Applicant respectfully submits that the rejoinder of Group I (claims 3-4, 9, 11, 14, 20, and 24; drawn to method of treating a patient having a chronic inflammatory disease with a blocking agent wherein the blocking agent is a peptide) would pose no undue burden on the Examiner. Applicant, therefore, respectfully requests rejoinder of the non-elected claims in Groups I with those in Group II.

Were restriction to be effected between the claims of Groups I-VII, a separate examination of the claims in these seven groups would require substantial duplication of work on the part of the U.S. Patent and Trademark Office. Even though some additional consideration would be necessary, the scope of analysis of novelty of all the claims of Groups I-VII would have to be as rigorous as when only the claims of Group II, for example, were being considered by themselves. Clearly, this duplication of effort would not be warranted where these claims of

Page 3 of 3

Response to Restriction Requirement

Applicant(s): Serial No.: Dominic COSGROVE 10/698,121

Senal i

31 October 2003

For:

INDUCIBLE LIGAND FOR a 1 \$1 INTEGRIN AND USES

different categories are so interrelated. Further, Applicant submits that for restriction to be effected between the claims in Groups I-VII, it would place an undue burden by requiring payment of six separate filing fees for examination of the nonelected claims, as well as the added costs associated with prosecuting six applications and maintaining seven patents.

The Examiner is invited to contact Applicant's Representatives, at the belowlisted telephone number if prosecution of this application may be assisted thereby.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1011 day of January, 2006, at

(Central Time),

Signature:

Printed Name:

Date¹

AMM/NAJ/kjm

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 Customer Number 26813

Nancy A. Johnson Reg. No. 47,266

Direct Dial (612)305-4723